SOPHiA GENETICS Confirms CEO Succession and Board Changes

SOPHiA GENETICS, a global leader in Ai-driven precision medicine, confirmed, ahead of its 2026 Annual General Meeting (AGM) scheduled for June 18, 2026, the leadership changes first announced in January 2026.

The Board has appointed Ross Muken, currently President, as Chief Executive Officer, effective July 1, 2026, and nominated him for election as a member of the Board of Directors. Furthermore, as set out in the AGM Invitation published on May 8, 2026, the Board of Directors has nominated Dr. Jurgi Camblong, co-founder and current Chief Executive Officer, for election as Chairman of the Board of Directors. Troy Cox, who has served as Chairman since March 2020, has been nominated for re-election as a non-executive member of the Board.

"Succession is one of the most important responsibilities of any Board, and I am proud of the disciplined, multi-year process that has led to today's announcement," said Troy Cox, Chairman of the Board of Directors of SOPHiA GENETICS. "Jurgi and Ross are exactly the right leaders for SOPHiA GENETICS at this moment: Jurgi's founder vision belongs at the Chair, and Ross's strategic, commercial, and operational track record make him the right CEO to scale the business through its next phase of growth. The Board is unanimous in its support, the process has been rigorous, and the timing is right. I look forward to continuing to serve on the Board and to supporting Ross, Jurgi, and the entire team as they execute on the next chapter of SOPHiA GENETICS' mission."